16-HETE 

16-HETE is arachidonic acid metabolite through subterminal hydroxylation by cytochrome P-450. 16-HETE exhibits vasodilatory and PMN inhibitory effects and serves as biomarker for early stages of non-alcoholic fatty liver disease^[1][2][3].

16-HETE (0.01-1 μM) specificially suppresses PMN aggregation and adhesion, with no significant effects on platelets function and blood pressure^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

16-HETE (1-20 μg, i.a.) is stereospecificially involved in vasodilation, regulation of renal perfusion and in mechanisms of tubular transport with S- enantiomer in New Zealand white rabbit^[2].
16-HETE (1 μg/kg/min) suppresses the increase of intracranial pressure (ICP) in a rabbit model of thromboembolic stroke^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

320.47

C₂₀H₃₂O₃

128914-46-5

CCCCC(O)/C=C\C/C=C\C/C=C\C/C=C\CCCC(O)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Bednar MM, et al., 16(R)-hydroxyeicosatetraenoic acid, a novel cytochrome P450 product of arachidonic acid, suppresses activation of human polymorphonuclear leukocyte and reduces intracranial pressure in a rabbit model of thromboembolic stroke. Neurosurgery. 2000 Dec;47(6):1410-8; discussion 1418-9.  [Content Brief]

  [2]. Carroll MA, e al., Cytochrome P-450-dependent HETEs: profile of biological activity and stimulation by vasoactive peptides. Am J Physiol. 1996 Oct;271(4 Pt 2):R863-9.  [Content Brief]

  [3]. Maciejewska D, et al., Metabolites of arachidonic acid and linoleic acid in early stages of non-alcoholic fatty liver disease--A pilot study. Prostaglandins Other Lipid Mediat. 2015 Sep;121(Pt B):184-9.  [Content Brief]